ASML vs. Intel: Which AI Chip Stock Is a Better Buy in 2026?

ASML raised its 2026 sales outlook to €43 billion-€45 billion from €34 billion-€39 billion in January after posting Q2 sales of €9.3 billion and a 54% gross margin, supported by sustained AI-driven EUV demand. Its fiscal-2025 revenue grew 15.6% to roughly $37.5 billion, with a 29.4% net margin and $12.2 billion in free cash flow; shares are up about 60% in 2026. Intel's Q2 revenue grew 25% and gross margin rose to 40.4% from 27.5%, but its foundry segment still lost $2.1 billion and fiscal-2025 free cash flow was negative $4.9 billion, leaving its turnaround dependent on execution.

Analysis

ASML’s scarcity value is not simply AI-capex beta: it is a toll collector on leading-edge node transitions across TSM, Samsung and Intel, with service revenue and installed-base utilization cushioning any individual customer’s capex pause. The more important 6-18 month variable is whether high-NA EUV adoption converts from engineering milestones into volume-tool orders; that would extend its pricing power and support another earnings-estimate reset. The principal near-term risk is not a technological substitute but order timing, China-export restrictions, and a customer digestion cycle after aggressive AI capacity builds—risks that can produce sharp multiple compression from an already demanding earnings base.

Intel’s equity case requires several independent outcomes: competitive process yields, external foundry customer commitments, sustained product-share stabilization, and capex discipline. Government alignment lowers financing and political-risk hurdles but can also reduce foundry appeal to non-U.S. customers that require supply-chain neutrality, particularly in Asia and the Middle East. A stronger Intel foundry ultimately expands ASML’s addressable tool demand; it is not a zero-sum competitor to ASML, although a prolonged Intel execution failure would remove a meaningful incremental EUV buyer.

Consensus is likely over-crediting the headline margin recovery at Intel before proof of foundry economics. The relevant validation is not revenue growth but external-wafer mix, foundry operating-loss trajectory, customer prepayments, and capex-to-revenue conversion. Conversely, ASML’s apparent relative safety is well understood; after a strong rerating, upside over the next 1-3 months likely requires bookings/backlog commentary or another 2027 capacity signal rather than merely meeting raised guidance.

Key Decisions for Investors

• Initiate a 6-12 month long ASML / short INTC dollar-neutral pair on a 5-8% pullback in ASML or following Intel strength. The trade isolates execution risk: ASML benefits from industry-wide leading-edge spend, while INTC must prove external foundry economics. Exit if ASML reports material order cancellations or Intel secures a sizable, named external leading-edge foundry customer with customer prepayments.
• Maintain ASML as the preferred core semiconductor-capex exposure, but scale rather than chase: add only after quarterly bookings validate 2027 tool demand. Use a roughly 12-15% downside risk limit from entry, as export-control expansion or a broad AI-capex digestion phase would impair both earnings visibility and the valuation multiple.
• Avoid adding outright INTC exposure ahead of foundry segment disclosure unless the next report shows sequential narrowing of foundry losses alongside credible external-volume commitments. A tactical long becomes actionable only if margin improvement is accompanied by lower cash burn; revenue growth funded by continued elevated capex is not sufficient.
• Monitor TSM’s capex commentary and advanced-node utilization as the highest-frequency read-through for ASML. A TSM capex cut or delayed leading-edge ramp would be a warning to reduce ASML before reported tool revenue weakens; a higher capex envelope supports retaining the ASML long despite near-term valuation risk.